Trials / Withdrawn
WithdrawnNCT04398680
A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function
A Phase I Study to Evaluate the Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Participants With Relapsed or Refractory Multiple Myeloma Who Have Normal and Varying Degrees of Impaired Hepatic Function (DREAMM 13)
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the pharmacokinetics (PK), safety, and tolerability of belantamab mafodotin monotherapy in Relapsed/Refractory Multiple Myeloma (RRMM) participants with impaired hepatic function and in matched RRMM participants with normal hepatic function.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Belantamab mafodotin | Belantamab mafodotin will be administered |
Timeline
- Start date
- 2021-04-20
- Primary completion
- 2025-11-04
- Completion
- 2025-11-04
- First posted
- 2020-05-21
- Last updated
- 2025-12-04
Locations
18 sites across 3 countries: United States, Greece, South Korea
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04398680. Inclusion in this directory is not an endorsement.